SEC Tracker
Get the app

Cytokinetics CYTK

T. Henderson John (Director) plans to sell 1,780 CYTK shares, about $89,979

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Dec 11, 2024
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Exercise of Stock Options
  4. 10b5-1 plan adopted: Sep 11, 2024

All of T. Henderson John's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 1,780 shares at $50.42 on Dec 11, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Cytokinetics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025
  2. Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
  3. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  4. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  5. Carisma Therapeutics CARM

Data on this page was fetched . The filing on SEC.gov is the record.